Director Share Purchase

RNS Number : 7377P

ReNeuron Group plc

21 October 2021

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Share Purchase by a Director

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed that on the 20 October 2021, the following purchase of the Company's ordinary shares of 1p each ("Ordinary Shares") was made by a director of the Company:

Name	Title	Number of Ordinary Shares purchased	Total beneficial interest in the Company's Ordinary Shares	Percentage of Company's Total Voting Rights
Barbara Staehelin	Senior Independent Non-Executive Director	43,000	43,000	0.08%

  ENDS

Contacts:

ReNeuron	www.reneuron.com/investors
Olav Hellebø, Chief Executive Officer Catherine Isted, Chief Financial Officer	Via Walbrook PR
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	[phone]
Allenby Capital Limited (Joint Broker)	[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 (Disclosure in relation to share options granted to Directors and PDMRs)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Barbara Staehelin
2	Reason for the notification
a)	Position/status	Senior Independent Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	Price(s)  Volume(s) 115p 43,000
d)	Aggregated information	£49,450
e)	Date of the transaction	20 October 2021
f)	Place of the transaction	London Stock Exchange AIM Market

 

END

 

 

DSHURVWRAAURUAA